Abstract
Clinical trials in hematopoietic malignancies at the Johns Hopkins Oncology Center are based on host induced biomodulation which determines the intervals of intensive timed chemotherapy. The aim is to define principles for the use of exogenous cytokines combined with those biologic activities in the intact host.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Burke PJ, Karp JE (1987) The relationship of the hematopoietic cycle to the combined activities of a stimulator and a short-lived inhibitor. Blood 69: 513–517
Burke PJ, Karp JE, Braine HG, Vaughan WP (1977) Timed sequential therapy of human leukemias based on response of leukemic cells to humoral growth factors. Cancer Res 37: 2138–2146
Burke PJ, Karp JE, Saylor PL (1980) Drug induced host factors which stimulate growth of residual leukemia in Lewis X Brown Norway F I (LEW-BN) rats. Can Res 46: 1813–1819
Burke PJ, Karp JE, Saylor PL (1989) Drug induced host factors which stimulate growth of residual leukemia in LEW-BN rats. Cancer Res 46: 1813–1816
Burke PJ, Karp JE, Vaughan WP (1981) Chemotherapy of leukemia in mice, rats, and humans relating time of humoral stimulation, tumor growth, and clinical response. JNCI 67: 529–532
Burke PJ, Karp JE, Vaughan WP, Sanford PL (1982) Recruitment of quiescent tumor by humoral stimulatory activity: Requirements for successful chemotherapy. Blood Cells 8: 519–533
Burke PJ, Vaughan WP, Karp JE, Sanford PL (1982) The correlation of maximal drug dose, tumor recruitment and sequence timing with therapeutic advantage: Schedule dependent toxicity of cytosine arabinoside. Med Ped Onc 1: 201–208
Burke PJ, Vaughan WP, Karp JE (1980) A rationale for sequential high dose chemotherapy ofleukemia timed to coincide with induced tumor proliferation. Blood 55: 950–968
Burke PJ, Vaughan WP, Karp JE, Jung JW, Garvin CC, Sanford PL, Chaneski JK (1980) A kinetic rationale for the therapy of malignancy related to predictable recruitment of leukemia in rat and man. In: Baum, SJ, Ledney, GD (eds) Exp Hematol Today, Springer-Verlag, New York
Ettinger DS, Karp JE, Abeloff MD, Burke PJ, Braine HG (1978) Intermittent high-dose cyclophosphamide chemotherapy in small cell carcinoma of the lung. Cancer Treat Rep 62: 413–424
Ganser A, Volkers B, Greher J (1990) Recombinant human granulocyte-macrophage colonystimulating factor in patients with myelodysplastic syndromes - A Phase I/II trial. Blood 73: 31–44
Geller RB, Burke PJ, Karp JE (1989) A two-step timed sequential treatment for acute myelocytic leukemia. Blood 74: 1499–1502
Karp JE, Burke PJ (1976) The influence of humoral regulators on proliferation and maturation of normal and leukemic cells. Cancer Res 36: 1974–1980
Karp JE, Burke PJ (1976) Enhancement of drug cytotoxicity of recruitment of)eukemic myeloblasts with humoral stimulation. Cancer Res 36: 3600–3609
Karp JE, Burke PJ, Donehower RC (1990) Effects of rh-GM-CSF on Intracellular ara-C Pharmacology In Vitro in Acute Myelocytic Leukemia: Comparability with Drug-Induced Humoral Stimulatory Activity. Leukemia 4: 553–565
Karp JE, Burke PJ, Humphrey RL (1977) Induction of serum stimulation and plasma cell proliferation during chemotherapy of multiple myeloma. Blood 49: 925–930
Karp JE, Burke PJ, Humphrey RL (1984) Correlation of proliferative and clonogenic tumor cells in multiple myeloma. Cancer Res 44: 4197–4204
Karp JE, Donehower RC, Dole GB, Burke PJ (1987) Correlation of Drug-Perturbed Marrow Cell Growth Kinetics and Intracellular I-B-DArabinofuranosylcytosine Metabolism with Clinical Response In Adult Acute Myelogenous Leukemia. Blood 69: 1134–1138
Karp JE, Donehower RC, Enterline JP, Dole GB, Fox MG, Burke PJ (1989) In Vivo Cell Growth and Pharmacologic Determinants of Clinical Response in Acute Myelogenous Leukemia. Blood 73: 24–31
Karp JE, Humphrey RL, Burke PJ (1981) Timed sequential chemotherapy of cytoxan refractory multiple myeloma with cytoxan and Adriamycin 540 based on induced tumor proliferation. Blood 57: 468–475
Vadhan-Raj S, Keating M, Lemaistre A (1990) Effects of recombinant human granulocytemacrophage colony-stimulating factor in patients with myelodysplastic syndromes. N Engl J Med 317: 1545–1551
Vaughan WP, Burke PJ (1983) Development in a rat model of a cell kinetic approach to curative therapy of acute myelocytic leukemia using the cell cycle specific drug I-B-D arabinofuranosyl cytosine. Cancer Res 43: 2005–2009
Vaughan WP, Karp JE, Burke PJ (1980) Long chemotherapy-free remissions after single-cycle timed-sequential chemotherapy for acute myelocytic leukemia. Cancer 45: 859–864
Vaughan WP, Karp JE, Burke PJ (1984) Two cycle timed sequential chemotherapy for adult acute non-lymphocytic leukemia. Blood 64: 975–981
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Burke, P.J. (1994). Recruitment of Leukemia with Combined Granulocyte-Macrophage and Host Stimulatory Factors. In: Büchner, T., Hiddemann, W., Wörmann, B., Schellong, G., Ritter, J. (eds) Acute Leukemias IV. Haematology and Blood Transfusion / Hämatologie und Bluttransfusion, vol 36. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78350-0_95
Download citation
DOI: https://doi.org/10.1007/978-3-642-78350-0_95
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-78352-4
Online ISBN: 978-3-642-78350-0
eBook Packages: Springer Book Archive